Thank you to everyone who joined us in Denver this week! Our community is what makes The Liver Meeting® what it is, and we’re grateful you were part of it.
Save the date for #TLM27 and we'll see you next year!
📍 Philadelphia, PA
🗓️ November 12 - 16, 2027
Great meeting. Nearly 9000 attendees , including 700 APPs, 400 patients, >2700 presentations. Largest exhibitor hall ever ! Fabulous city and convention center. Note that nearly all talks are recorded and there is cc in 15 languages, so can catch what younmissed. Philly in 2027!
Thank you to everyone who joined us in Denver this week! Our community is what makes The Liver Meeting® what it is, and we’re grateful you were part of it.
Save the date for #TLM27 and we'll see you next year!
📍 Philadelphia, PA
🗓️ November 12 - 16, 2027
🏠 Hospital at Home for liver disease?
Early studies suggest this model may be safe and feasible for selected patients with cirrhosis. This review covers the evidence, care delivery, and challenges to broader implementation.
doi.org/10.1097/LVT.00000000…
Another successful @AST_info@AST_LICOP Education Committee meeting @AASLDtweets#TLM26.
Such a productive and amazing group. Looking forward to the ongoing impactful work of our members! 🙌
🩸 Can frailty in cirrhosis be assessed without an in-person visit?
In 527 patients, the 7-biomarker Lab-LFI showed good discrimination for frailty (c-statistic 0.80). High scores were independently linked to pre-LT mortality/waitlist dropout (HR 1.77).
doi.org/10.1097/LVT.00000000…
Everyone in hepatology and liver transplant is aware of Jennifer C. Lai, MD/MBA’s impact. This week we were privileged to have her as the Sheila Sherlock visiting professor at Michigan Hepatology
Donor BMI rises, liver biopsy use in LDLT is plummeting.
🇺🇸 In 7,942 LDLTs (2000–2024), donor BMI rose 24.6→27.6, while biopsy use fell ~50%→6%. Higher BMI was not linked to worse recipient outcomes.
Time to standardize steatosis assessment?
doi.org/10.1097/LVT.00000000…#LiverX
Can a deceased donor–derived predictor guide decisions in living donor LT for ACLF? 🧐
In 178 LDLT recipients, SALT-M showed limited discrimination (AUROC 0.56).
Model failure or simply a different patient population? Use with caution ☝️
🔗 doi.org/10.1097/LVT.00000000…
Why does portal vein thrombosis matter in hospitalized patients with cirrhosis?
In the global CLEARED cohort investigating 7,721 patients across 37 countries, PVT affected 1 in 10 and was linked to more AKI, severe HE, and higher 30-day mortality.
doi.org/10.1097/LVT.00000000…#LiverX